Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Revive Therapeutics Ltd C.RVV

Alternate Symbol(s):  RVVTF

Revive Therapeutics Ltd. is a Canada-based life sciences company. The Company is focused on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders. It is engaged in exploring the use of Bucillamine for the potential treatment of nerve agent exposure and long COVID. The Company, through its diagnostics division, is... see more

CSE:RVV - Post Discussion

Revive Therapeutics Ltd > The FDA is finally giving out EUA For Covid-19 Meds :)
View:
Post by TheTerminator1 on May 28, 2021 8:52am

The FDA is finally giving out EUA For Covid-19 Meds :)

RVV's 16x more powerful but safe Bucillamine will soon make the headlines...

Stick around,we are as close as you can be to receiving a well deserved EUA

Only the patient get to eat the cake
Comment by captainbrouwer on May 29, 2021 5:06am
Was going to ask for a source but found one myself https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-additional-monoclonal-antibody-treatment-covid-19
Comment by 1ottrunner on May 29, 2021 8:06am
EUA was offered at 583 patients. Can the Bucillamine trial possibly not be at that milestone?  With 31 sites the trial would only need to recruit 20 participants per site.
Comment by CrazyProphet on May 29, 2021 8:35am
Potential side effects of sotrovimab include anaphylaxis and infusion-related reactions, rash and diarrhea.   
Comment by cool888 on May 29, 2021 8:44am
The safety of Sotrovimab is primarily based on an interim analysis from 868 patients (430 patients in the treatment arm and 438 in the placebo arm) through day 15. Really FDA ? Another Big Pharma gets a "quick" EUA !! https://www.fda.gov/media/149533/download https://www.businesstoday.in/sectors/pharma/new-drug-to-treat-covid-19-sotrovimab-to-soon-launch-in-india/story/440143.html
Comment by cool888 on May 29, 2021 8:42pm
I don't care what "Mr. Genius" says to which I DO NOT care, FDA IS CORRUPTED big time !
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities